Gahan Pandina1, Seth Ness2, Jeremiah Trudeau3, Sonja Stringer4, Naomi Knoble4, William R Lenderking4, Abigail Bangerter2. 1. Department of Neuroscience, Janssen Research & Development, LLC, Pennington, NJ, 08534, USA. gpandina@its.jnj.com. 2. Department of Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA. 3. Department of Patient Reported Outcomes, Janssen Global Services, Raritan, NJ, USA. 4. Evidera, Pharmaceutical Product Development, LLC, Bethesda, MD, USA.
Abstract
PURPOSE: The Autism Behavior Inventory (ABI) is an observer-reported outcome scale measuring core and associated features of autism spectrum disorder (ASD). Extensive scale development (reported elsewhere) took place, in alignment with the Food and Drug Administration's patient-reported outcome guidance, to address the need for instruments to measure change and severity of ASD symptoms. METHODS: Cognitive interviewing was used to confirm understanding and content validity of the scale prior to its use in clinical trials. Respondents were caregivers of individuals with ASD (N = 50). Interviews used a hybrid of the "think-aloud" and verbal probing approach to assess ABI's content validity and participant understanding of the instrument, including: item clarity and relevance; item interpretation; appropriateness of response scales; and clarity of instructions. Audio-recordings of the interviews were transcribed for qualitative data analysis. The scale was revised based on participant feedback and tested in a second round of interviews (round 1 N = 38, round 2 N = 12). RESULTS: In total, 67/70 items reached ≥ 90% understandability across participants. Caregivers were able to select an appropriate response from the options available and reported finding the examples helpful. Based on participant feedback, instructions were simplified, 8 items were removed, and 10 items were reworded. The final revised 62-item scale was presented in round 2, where caregivers reported readily understanding the instructions, response options, and 61/62 items reached ≥ 90% understandability. CONCLUSIONS: Cognitive interviews with caregivers of a diverse sample of individuals with ASD confirm the content validity and relevance of the ABI to assess core and associated symptoms of ASD.
PURPOSE: The Autism Behavior Inventory (ABI) is an observer-reported outcome scale measuring core and associated features of autism spectrum disorder (ASD). Extensive scale development (reported elsewhere) took place, in alignment with the Food and Drug Administration's patient-reported outcome guidance, to address the need for instruments to measure change and severity of ASD symptoms. METHODS: Cognitive interviewing was used to confirm understanding and content validity of the scale prior to its use in clinical trials. Respondents were caregivers of individuals with ASD (N = 50). Interviews used a hybrid of the "think-aloud" and verbal probing approach to assess ABI's content validity and participant understanding of the instrument, including: item clarity and relevance; item interpretation; appropriateness of response scales; and clarity of instructions. Audio-recordings of the interviews were transcribed for qualitative data analysis. The scale was revised based on participant feedback and tested in a second round of interviews (round 1 N = 38, round 2 N = 12). RESULTS: In total, 67/70 items reached ≥ 90% understandability across participants. Caregivers were able to select an appropriate response from the options available and reported finding the examples helpful. Based on participant feedback, instructions were simplified, 8 items were removed, and 10 items were reworded. The final revised 62-item scale was presented in round 2, where caregivers reported readily understanding the instructions, response options, and 61/62 items reached ≥ 90% understandability. CONCLUSIONS: Cognitive interviews with caregivers of a diverse sample of individuals with ASD confirm the content validity and relevance of the ABI to assess core and associated symptoms of ASD.
Authors: Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring Journal: Value Health Date: 2011-10-10 Impact factor: 5.725
Authors: Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring Journal: Value Health Date: 2011-10-13 Impact factor: 5.725
Authors: Lawrence Scahill; Michael G Aman; Luc Lecavalier; Alycia K Halladay; Somer L Bishop; James W Bodfish; Sabrina Grondhuis; Nancy Jones; Joseph P Horrigan; Edwin H Cook; Benjamin L Handen; Bryan H King; Deborah A Pearson; James T McCracken; Katherine Anne Sullivan; Geraldine Dawson Journal: Autism Date: 2013-11-20
Authors: Margaret Rothman; Laurie Burke; Pennifer Erickson; Nancy Kline Leidy; Donald L Patrick; Charles D Petrie Journal: Value Health Date: 2009-09-25 Impact factor: 5.725
Authors: Seth L Ness; Abigail Bangerter; Nikolay V Manyakov; David Lewin; Matthew Boice; Andrew Skalkin; Shyla Jagannatha; Meenakshi Chatterjee; Geraldine Dawson; Matthew S Goodwin; Robert Hendren; Bennett Leventhal; Frederick Shic; Jean A Frazier; Yvette Janvier; Bryan H King; Judith S Miller; Christopher J Smith; Russell H Tobe; Gahan Pandina Journal: Front Neurosci Date: 2019-02-27 Impact factor: 4.677
Authors: Abigail Bangerter; Nikolay V Manyakov; David Lewin; Matthew Boice; Andrew Skalkin; Shyla Jagannatha; Meenakshi Chatterjee; Geraldine Dawson; Matthew S Goodwin; Robert Hendren; Bennett Leventhal; Frederick Shic; Seth Ness; Gahan Pandina Journal: JMIR Ment Health Date: 2019-03-26
Authors: Seth L Ness; Nikolay V Manyakov; Abigail Bangerter; David Lewin; Shyla Jagannatha; Matthew Boice; Andrew Skalkin; Geraldine Dawson; Yvette M Janvier; Matthew S Goodwin; Robert Hendren; Bennett Leventhal; Frederick Shic; Walter Cioccia; Gahan Pandina Journal: Front Neurosci Date: 2017-09-26 Impact factor: 4.677
Authors: Helen McConachie; Nuala Livingstone; Christopher Morris; Bryony Beresford; Ann Le Couteur; Paul Gringras; Deborah Garland; Glenys Jones; Geraldine Macdonald; Katrina Williams; Jeremy R Parr Journal: J Autism Dev Disord Date: 2018-04